- Home
- MAZE vs NMAI Comparison
MAZE vs NMAI Comparison
Compare MAZE & NMAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAZE
- NMAI
- Stock Information
- Founded
- MAZE 2018
- NMAI 2021
- Country
- MAZE United States
- NMAI United States
- Employees
- MAZE N/A
- NMAI N/A
- Industry
- MAZE
- NMAI Investment Managers
- Sector
- MAZE
- NMAI Finance
- Exchange
- MAZE NYSE
- NMAI Nasdaq
- Market Cap
- MAZE 367.0M
- NMAI 422.8M
- IPO Year
- MAZE 2025
- NMAI N/A
- Fundamental
- Price
- MAZE $11.43
- NMAI $12.43
- Analyst Decision
- MAZE Strong Buy
- NMAI
- Analyst Count
- MAZE 3
- NMAI 0
- Target Price
- MAZE $25.67
- NMAI N/A
- AVG Volume (30 Days)
- MAZE 100.1K
- NMAI 74.8K
- Earning Date
- MAZE 08-14-2025
- NMAI 01-01-0001
- Dividend Yield
- MAZE N/A
- NMAI 13.14%
- EPS Growth
- MAZE N/A
- NMAI N/A
- EPS
- MAZE 0.34
- NMAI 0.64
- Revenue
- MAZE $167,500,000.00
- NMAI N/A
- Revenue This Year
- MAZE N/A
- NMAI N/A
- Revenue Next Year
- MAZE N/A
- NMAI N/A
- P/E Ratio
- MAZE $30.79
- NMAI $19.03
- Revenue Growth
- MAZE N/A
- NMAI N/A
- 52 Week Low
- MAZE $6.71
- NMAI $10.60
- 52 Week High
- MAZE $17.00
- NMAI $12.55
- Technical
- Relative Strength Index (RSI)
- MAZE N/A
- NMAI 55.44
- Support Level
- MAZE N/A
- NMAI $12.23
- Resistance Level
- MAZE N/A
- NMAI $12.68
- Average True Range (ATR)
- MAZE 0.00
- NMAI 0.12
- MACD
- MAZE 0.00
- NMAI -0.02
- Stochastic Oscillator
- MAZE 0.00
- NMAI 47.35
About MAZE MAZE THERAPEUTICS INC
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
About NMAI Nuveen Multi-Asset Income Fund of Beneficial Interest
Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment strategy uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund may invest in equity and debt securities of any type without limit.